

Taigo Kato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6549752/publications.pdf>

Version: 2024-02-01

56
papers

1,308
citations

331670

21
h-index

395702

33
g-index

58
all docs

58
docs citations

58
times ranked

1933
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut Microbiotaâ€“Derived Short-Chain Fatty Acids Promote Prostate Cancer Growth via IGF1 Signaling. <i>Cancer Research</i> , 2021, 81, 4014-4026.	0.9	83
2	A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. <i>Oncotarget</i> , 2018, 9, 18985-18996.	1.8	83
3	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptorâ€“Engineered T Cells for Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5357-5367.	7.0	70
4	CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	68
5	T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6110-6117.	7.0	63
6	Diagnostic potential of <i>TERT</i> promoter and <i>FGFR3</i> mutations in urinary cell-free DNA in upper tract urothelial carcinoma. <i>Cancer Science</i> , 2019, 110, 1771-1779.	3.9	63
7	Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. <i>Cancer Science</i> , 2019, 110, 617-628.	3.9	61
8	Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5390.	4.1	48
9	Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. <i>Oncotarget</i> , 2018, 9, 11009-11019.	1.8	44
10	Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. <i>Oncotarget</i> , 2016, 7, 17652-17664.	1.8	44
11	Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 13621-13633.	1.8	41
12	Germline PARP4 mutations in patients with primary thyroid and breast cancers. <i>Endocrine-Related Cancer</i> , 2016, 23, 171-179.	3.1	39
13	Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma. <i>Oncotarget</i> , 2018, 9, 20467-20475.	1.8	38
14	Proteomic analysis of urinary and tissueâ€“exudative extracellular vesicles to discover novel bladder cancer biomarkers. <i>Cancer Science</i> , 2021, 112, 2033-2045.	3.9	35
15	p53-independent p21 induction by MELK inhibition. <i>Oncotarget</i> , 2017, 8, 57938-57947.	1.8	35
16	Characterization of the cryoablation-induced immune response in kidney cancer patients. <i>Oncolmmunology</i> , 2017, 6, e1326441.	4.6	34
17	Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2019, 8, e1568813.	4.6	31
18	TOPK (Tâ€“LAK cellâ€“originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. <i>Cancer Science</i> , 2017, 108, 488-496.	3.9	28

#	ARTICLE	IF	CITATIONS
19	The role of actinin-4 (ACTN4) in exosomes as a potential novel therapeutic target in castration-resistant prostate cancer. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 588-594.	2.1	28
20	Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. <i>Oncotarget</i> , 2017, 8, 62029-62038.	1.8	28
21	Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown. <i>Neoplasia</i> , 2016, 18, 265-272.	5.3	27
22	Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6220.	3.3	25
23	Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma. <i>Oncolmmunology</i> , 2021, 10, 1862948.	4.6	20
24	MicroRNA-92b-3p is a prognostic oncomiR that targets <i>TSC1</i> in clear cell renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1146-1155.	3.9	19
25	The benefits of cancer screening in kidney transplant recipients: a single-center experience. <i>Cancer Medicine</i> , 2016, 5, 153-158.	2.8	18
26	TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. <i>Oncolmmunology</i> , 2019, 8, e1588085.	4.6	17
27	Leukocyte-associated immunoglobulin-like receptor γ 1/2 promotes tumorigenesis in RCC. <i>Oncology Reports</i> , 2019, 41, 1293-1303.	2.6	16
28	The era of immunogenomics/immunopharmacogenomics. <i>Journal of Human Genetics</i> , 2018, 63, 865-875.	2.3	15
29	Oral Administration of Si-Based Agent Attenuates Oxidative Stress and Ischemia-Reperfusion Injury in a Rat Model: A Novel Hydrogen Administration Method. <i>Frontiers in Medicine</i> , 2020, 7, 95.	2.6	15
30	Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long-term multicenter cohort study. <i>Cancer Medicine</i> , 2021, 10, 2205-2215.	2.8	15
31	Trop-2 in Upper Tract Urothelial Carcinoma. <i>Current Oncology</i> , 2022, 29, 3911-3921.	2.2	13
32	Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer. <i>Cancer Science</i> , 2020, 111, 1692-1698.	3.9	12
33	High-fat diet promotes prostate cancer growth through histamine signaling. <i>International Journal of Cancer</i> , 2022, 151, 623-636.	5.1	12
34	Clinical Efficacy of Intravenous Immunoglobulin for BK Polyomavirus-Associated Nephropathy After Living Kidney Transplantation. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 947-952.	2.0	11
35	Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma. <i>Cancer Science</i> , 2022, 113, 1830-1842.	3.9	11
36	Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1596-1604.	2.2	11

#	ARTICLE	IF	CITATIONS
37	Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma. <i>International Immunology</i> , 2020, 32, 347-357.	4.0	10
38	Therapeutic and Clinical Outcomes of Robot-assisted Partial Nephrectomy versus Cryoablation for T1 Renal Cell Carcinoma. <i>In Vivo</i> , 2021, 35, 1573-1579.	1.3	9
39	The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 954-961.	2.2	9
40	Phenotypic Analysis of Tumor Tissue-Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 114-124.	1.9	8
41	A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma. <i>Anticancer Research</i> , 2020, 40, 4875-4883.	1.1	6
42	Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone. <i>IJU Case Reports</i> , 2021, 4, 22-24.	0.3	6
43	Fragmentation of cell-free DNA is induced by upper-tract urothelial carcinoma-associated systemic inflammation. <i>Cancer Science</i> , 2021, 112, 168-177.	3.9	6
44	Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of <i>in vitro</i> expanded populations in head and neck cancer. <i>Oncotarget</i> , 2018, 9, 3805-3814.	1.8	6
45	Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2022, 29, 462-469.	1.0	6
46	Efficacy of a Si-based agent against developing renal failure in a rat remnant kidney model. <i>Biochemical and Biophysical Research Communications</i> , 2020, 533, 698-703.	2.1	4
47	Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 5811-5816.	1.1	4
48	Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2999-3011.	4.2	4
49	Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 78-86.	2.2	3
50	Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 249.	2.4	3
51	Resumption of anti-programmed cell death 1 monotherapy for severe immune-related adverse events experienced patient with renal cell carcinoma. <i>IJU Case Reports</i> , 2020, 3, 176-179.	0.3	1
52	A case of perirenal non-specific lymphadenitis mimicking a solitary renal mass. <i>IJU Case Reports</i> , 2022, 5, 10-13.	0.3	1
53	Incidence and mortality of post-transplant lymphoproliferative disorders after kidney transplantation: A real-world retrospective analysis in Japan. <i>International Journal of Urology</i> , 2022, 29, 206-211.	1.0	1
54	Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space. <i>IJU Case Reports</i> , 2021, 4, 255-258.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Editorial Comment from Dr. Kato to Recurrent urinary retention due to clots caused by a congenital renal arteriovenous malformation that forms a complex vascular network: Report of two cases. IJU Case Reports, 2022, 5, 8-9.	0.3	0
56	Editorial Comment to Determining programmed cell death ligand 1 expression in circulating tumor cells of patients with clear cell renal cell carcinoma and its correlation with response to programmed cell death protein 1 inhibitors. International Journal of Urology, 2022, 29, 954-955.	1.0	0